v3.26.1
Unaudited Condensed Statements of Changes in Consolidated Shareholders' Equity
$ in Thousands, € in Millions
USD ($)
shares
Share Capital Ordinary Shares [member]
shares
Share Capital Preference Shares [Member]
shares
Issued capital [member]
USD ($)
Premiums Related to Share Capital [member]
USD ($)
Premiums Related to Share Capital [member]
EUR (€)
Currency Translation Adjustment [member]
USD ($)
Retained Earnings (Deficit) [member]
USD ($)
Income (loss) [member]
USD ($)
Beginning balance at Dec. 31, 2024 $ 131,033     $ 5,889 $ 494,288   $ (39,537) $ (292,846) $ (36,761)
Beginning balance, shares at Dec. 31, 2024 | shares   72,093,873 28,000,000            
Net income (loss) (41,863)               (41,863)
Other comprehensive income (loss) 5,683           5,652 31  
Total Comprehensive income (loss) $ (36,180)           5,652 31 (41,863)
Allocation of prior period loss         (63,000) € 58.2   26,239 [1] 36,761 [1]
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, amount       13 3     (15)  
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, shares | shares 231,356 231,356              
Non-cash stock-based compensation expense $ 2,258       2,258        
Ending balance at Jun. 30, 2025 97,111     5,902 433,549   (33,885) (266,592) (41,863)
Ending balance, shares at Jun. 30, 2025 | shares   72,325,229 28,000,000            
Beginning balance at Dec. 31, 2025 75,901     5,903 437,445   (33,316) (266,538) (67,593)
Beginning balance, shares at Dec. 31, 2025 | shares   72,339,441 28,000,000            
Net income (loss) (39,584)               (39,584)
Other comprehensive income (loss) 592           638 (45)  
Total Comprehensive income (loss) (38,992)           638 (45) (39,584)
Allocation of prior period loss         (69,800) € 61.8   2,254 [2] 67,593 [2]
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, amount $ 204     21 [3] 198 [3]     (15)  
Exercise of share warrants, employee warrants, stock-options and free-shares vesting, shares | shares 358,717 [3] 358,717              
Non-cash stock-based compensation expense $ 3,952       3,952        
Ending balance at Jun. 30, 2026 $ 41,066     $ 5,924 $ 371,749   $ (32,679) $ (264,344) $ (39,584)
Ending balance, shares at Jun. 30, 2026 | shares   72,698,158 28,000,000            
[1] The standalone statutory loss for the year ended December 31, 2024 of the parent company was allocated to premiums related to share capital for 58.2 million euros or approximately $63.0 million following the decision of the Annual General Meeting of shareholders which took place on June 26, 2025. The difference between this standalone statutory loss of the parent company and the consolidated net loss was allocated to retained deficit for $26.2 million.
[2] The standalone statutory loss for the year ended December 31, 2025 of the parent company was allocated to premiums related to share capital for 61.8 million euros or approximately 69.8 million U.S. dollars following the decision of the Annual General Meeting of shareholders which took place on June 25, 2026. The difference between this standalone statutory loss of the parent company and the consolidated net loss was allocated to retained deficit for $2.3 million.
[3] During the six-month period ended June 30, 2026, 358,717 ordinary shares were issued to the benefit of Cellectis employees related to free share plans which met vesting conditions and exercises of stock-options.